Molecular Pharmacology (USA) Limited (Molecular USA) is an Australia-based development Stage company together with its subsidiary, Molecular Pharmacology Pty. Ltd. (MPLA) is in the business of developing and commercializing an analgesic and anti-inflammatory molecule known as Tripeptofen. The Company’s over-the-counter anti-pain and anti-inflammatory products sold for the treatment of acute localized pain are based on non-steroidal anti-inflammatory drugs (NSAIDs). The licensed products include all products in all dosage forms, formulations, line extensions and package configurations using production method of metallo-polypeptide analgesic and anti-inflammatory activity as an active ingredient marketed by MPLA or its affiliates under the trade name Tripeptofen. The Company and Molecular Pharmacology Pty. Ltd. have no manufacturing facilities.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)